Upcoming

2023

Non-steroidal Anti-inflammatory Drugs (nsaids) Market

Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market

by Disease Indication (Arthritis, Migraine, Ophthalmic Diseases, Others), by Route of Administration (Oral, Parenteral) and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals	Report Code: A13374	Nov 2023 \| Pages: NA
Tables: NA	Charts: NA	Formats*: Single User License, Five User License & Enterprise User License Data Pack Excel License It comes with the additional cost of $2500.00 contact sales.

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Non-steroidal Anti-inflammatory Drugs (nsaids) Market

Request Now !

Non-steroidal anti-inflammatory drugs are used to treat pain, high fever, and prevention of blood clots. Moreover, when high doses of non-steroidal anti-inflammatory drugs (NSAIDs) are administered, the inflammation is reduced. The non-steroidal drugs having depressing and anti-inflammatory action. Non-steroidal anti-inflammatory drugs (NSAIDs) works by inhibiting the COX-1 and COX-2 enzymes, which are responsible for inflammation. Paracetamol, ibuprofen, aspirin, and naproxen are common types of non-steroidal anti-inflammatory drugs.

COVID-19 Impact Analysis

COVID-19 is an infectious disease that first emerged in late December in Hubei province of the Wuhan city in China. The virus that causes, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is highly infectious and is transmitted from person to person. Since the outbreak in December 2019, the disease has spread to across 213 countries around the globe with the World Health Organization declaring it a pandemic on March 11, 2020.

Pharmaceutical and biotech companies along with governments around the globe are working to address the COVID-19 outbreak, from supporting the vaccines development to medicine supply chain planning. Approximately, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a significant increase in demand for the treatment of COVID-19. Such increased demand for these drugs has offered huge opportunities for manufacturers of COVID-19 treatment drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future due to the demand for vaccine and the treatment drugs for COVID-19. This in anticipated to have a significant impact on the non-steroidal anti-Inflammatory drugs (NSAIDs) market.

Top Impacting Factors

Rise in chronic pain cases, the surge in inflammation cases, preference of non-steroidal anti-inflammatory drugs (NSAIDs) over the opioids, increase in geriatric population, rise in awareness about the use of non-steroidal anti-inflammatory drugs (NSAIDs) and constant increase in business strategies are factors that drive the growth of the non-steroidal anti-inflammatory drugs (NSAIDs) market.
Furthermore, increase in non-steroidal anti-inflammatory drugs (NSAIDs) adoption, advantages and effectiveness using non-steroidal anti-inflammatory drugs (NSAIDs), low cost of treatment, rise in demand for non-steroidal anti-inflammatory drugs (NSAIDs), emerging technology in developing countries, research and development activities, and launch of novel drugs are the key factors that boost the growth of the non-steroidal anti-inflammatory drugs (NSAIDs) market.
However, side effects associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs) such as dizziness, nausea, and allergic reactions can limit the growth of the non-steroidal anti-inflammatory drugs (NSAIDs) market.
Quick authority approvals by the governments and increase in government initiatives raised awareness and funding in this market are anticipated to provide lucrative opportunities for the expansion of the market.

Market Trend

New R & D Activities to Develop Novel NSAID Products

The U.S. Food and Drug Administration (USFDA) approved over-the-counter diclofenac sodium skin gel 1% of Perrigo Company plc in May 2019. This product provides chronic pain relief.

Teva Pharmaceutical Industries Ltd. announced the launch of Flector 1 Patch in March 2019. The product was released in the U.S. market. It is a non-steroidal anti-inflammatory drug (NSAID) that is used to treat chronic pain caused by minor wounds, injuries, and strains

Key Benefits of the Report

This study presents the analytical depiction of Non-steroidal Anti-Inflammatory Drugs (NSAIDs) industry along with the current trends and future estimations to determine the imminent investment pockets.
The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the Non-steroidal Anti-Inflammatory Drugs (NSAIDs) market share.
The current market is quantitatively analyzed to highlight the growth scenario of the Non-steroidal Anti-Inflammatory Drugs (NSAIDs) market.
Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
The report provides a detailed Non-steroidal Anti-Inflammatory Drugs (NSAIDs) market analysis based on competitive intensity and the that competition will take shape in coming years

Questions answered in the Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Report

Who are the leading market players active in the Non-steroidal Anti-Inflammatory Drugs (NSAIDs) market?
What current trends will influence the market in the next few years?
What are the driving factors, restraints, and opportunities in the market?
What are the future projections that would help in taking further strategic steps?
What is "Non-steroidal Anti-Inflammatory Drugs (NSAIDs)"?
What is the prediction of the "Non-steroidal Anti-Inflammatory Drugs (NSAIDs)" Market in the future?
Who are the leading global players in the "Non-steroidal Anti-Inflammatory Drugs (NSAIDs)" Market?
What are the current and predicted trends?
What are the key benefits of the "Non-steroidal Anti-Inflammatory Drugs (NSAIDs)" Market report?

Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Report Highlights

Aspects	Details
By Disease Indication	Arthritis Migraine Ophthalmic Diseases Others
By Route of Administration	Oral Parenteral
By Distribution Channel	Hospital Pharmacy Retail Pharmacy Online Pharmacy
By Region	North America (U.S., Canada, Mexico) Europe (France, Germany, Italy, Spain, UK, Rest of Europe) Asia-Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific) LAMEA (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players	Bayer AG, Johnson and Johnson Services, Inc., Depomed, Pfizer Inc., Yunnan Baiyao, Allergan, Grunenthal, Endo, Teva, Merck, Sanofi, AstraZeneca, GSK plc, Purdue, Eli Lilly

CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
  - 1.4.1. Primary Research
  - 1.4.2. Secondary Research
  - 1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
  - 3.2.1. Top Investment Pockets
  - 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
  - 3.3.1. Bargaining Power of Suppliers
  - 3.3.2. Threat of New Entrants
  - 3.3.3. Threat of Substitutes
  - 3.3.4. Competitive Rivalry
  - 3.3.5. Bargaining Power among Buyers
- 3.5. Market Dynamics
  - 3.5.1. Drivers
  - 3.5.2. Restraints
  - 3.5.3. Opportunities
- 3.6. COVID-19 Impact Analysis
CHAPTER 4: NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET, BY DISEASE INDICATION
- 4.1. Market Overview
  - 4.1.1 Market Size and Forecast, By Disease Indication
- 4.2. Arthritis
  - 4.2.1. Key Market Trends, Growth Factors and Opportunities
  - 4.2.2. Market Size and Forecast, By Region
  - 4.2.3. Market Share Analysis, By Country
- 4.3. Migraine
  - 4.3.1. Key Market Trends, Growth Factors and Opportunities
  - 4.3.2. Market Size and Forecast, By Region
  - 4.3.3. Market Share Analysis, By Country
- 4.4. Ophthalmic Diseases
  - 4.4.1. Key Market Trends, Growth Factors and Opportunities
  - 4.4.2. Market Size and Forecast, By Region
  - 4.4.3. Market Share Analysis, By Country
- 4.5. Others
  - 4.5.1. Key Market Trends, Growth Factors and Opportunities
  - 4.5.2. Market Size and Forecast, By Region
  - 4.5.3. Market Share Analysis, By Country
CHAPTER 5: NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET, BY ROUTE OF ADMINISTRATION
- 5.1. Market Overview
  - 5.1.1 Market Size and Forecast, By Route Of Administration
- 5.2. Oral
  - 5.2.1. Key Market Trends, Growth Factors and Opportunities
  - 5.2.2. Market Size and Forecast, By Region
  - 5.2.3. Market Share Analysis, By Country
- 5.3. Parenteral
  - 5.3.1. Key Market Trends, Growth Factors and Opportunities
  - 5.3.2. Market Size and Forecast, By Region
  - 5.3.3. Market Share Analysis, By Country
CHAPTER 6: NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Market Overview
  - 6.1.1 Market Size and Forecast, By Distribution Channel
- 6.2. Hospital Pharmacy
  - 6.2.1. Key Market Trends, Growth Factors and Opportunities
  - 6.2.2. Market Size and Forecast, By Region
  - 6.2.3. Market Share Analysis, By Country
- 6.3. Retail Pharmacy
  - 6.3.1. Key Market Trends, Growth Factors and Opportunities
  - 6.3.2. Market Size and Forecast, By Region
  - 6.3.3. Market Share Analysis, By Country
- 6.4. Online Pharmacy
  - 6.4.1. Key Market Trends, Growth Factors and Opportunities
  - 6.4.2. Market Size and Forecast, By Region
  - 6.4.3. Market Share Analysis, By Country
CHAPTER 7: NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET, BY REGION
- 7.1. Market Overview
  - 7.1.1 Market Size and Forecast, By Region
- 7.2. North America
  - 7.2.1. Key Market Trends and Opportunities
  - 7.2.2. Market Size and Forecast, By Disease Indication
  - 7.2.3. Market Size and Forecast, By Route Of Administration
  - 7.2.4. Market Size and Forecast, By Distribution Channel
  - 7.2.5. Market Size and Forecast, By Country
  - 7.2.6. U.S. Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.2.6.1. Market Size and Forecast, By Disease Indication
    - 7.2.6.2. Market Size and Forecast, By Route Of Administration
    - 7.2.6.3. Market Size and Forecast, By Distribution Channel
  - 7.2.7. Canada Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.2.7.1. Market Size and Forecast, By Disease Indication
    - 7.2.7.2. Market Size and Forecast, By Route Of Administration
    - 7.2.7.3. Market Size and Forecast, By Distribution Channel
  - 7.2.8. Mexico Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.2.8.1. Market Size and Forecast, By Disease Indication
    - 7.2.8.2. Market Size and Forecast, By Route Of Administration
    - 7.2.8.3. Market Size and Forecast, By Distribution Channel
- 7.3. Europe
  - 7.3.1. Key Market Trends and Opportunities
  - 7.3.2. Market Size and Forecast, By Disease Indication
  - 7.3.3. Market Size and Forecast, By Route Of Administration
  - 7.3.4. Market Size and Forecast, By Distribution Channel
  - 7.3.5. Market Size and Forecast, By Country
  - 7.3.6. France Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.3.6.1. Market Size and Forecast, By Disease Indication
    - 7.3.6.2. Market Size and Forecast, By Route Of Administration
    - 7.3.6.3. Market Size and Forecast, By Distribution Channel
  - 7.3.7. Germany Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.3.7.1. Market Size and Forecast, By Disease Indication
    - 7.3.7.2. Market Size and Forecast, By Route Of Administration
    - 7.3.7.3. Market Size and Forecast, By Distribution Channel
  - 7.3.8. Italy Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.3.8.1. Market Size and Forecast, By Disease Indication
    - 7.3.8.2. Market Size and Forecast, By Route Of Administration
    - 7.3.8.3. Market Size and Forecast, By Distribution Channel
  - 7.3.9. Spain Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.3.9.1. Market Size and Forecast, By Disease Indication
    - 7.3.9.2. Market Size and Forecast, By Route Of Administration
    - 7.3.9.3. Market Size and Forecast, By Distribution Channel
  - 7.3.10. UK Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.3.10.1. Market Size and Forecast, By Disease Indication
    - 7.3.10.2. Market Size and Forecast, By Route Of Administration
    - 7.3.10.3. Market Size and Forecast, By Distribution Channel
  - 7.3.11. Russia Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.3.11.1. Market Size and Forecast, By Disease Indication
    - 7.3.11.2. Market Size and Forecast, By Route Of Administration
    - 7.3.11.3. Market Size and Forecast, By Distribution Channel
  - 7.3.12. Rest Of Europe Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.3.12.1. Market Size and Forecast, By Disease Indication
    - 7.3.12.2. Market Size and Forecast, By Route Of Administration
    - 7.3.12.3. Market Size and Forecast, By Distribution Channel
- 7.4. Asia-Pacific
  - 7.4.1. Key Market Trends and Opportunities
  - 7.4.2. Market Size and Forecast, By Disease Indication
  - 7.4.3. Market Size and Forecast, By Route Of Administration
  - 7.4.4. Market Size and Forecast, By Distribution Channel
  - 7.4.5. Market Size and Forecast, By Country
  - 7.4.6. China Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.4.6.1. Market Size and Forecast, By Disease Indication
    - 7.4.6.2. Market Size and Forecast, By Route Of Administration
    - 7.4.6.3. Market Size and Forecast, By Distribution Channel
  - 7.4.7. Japan Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.4.7.1. Market Size and Forecast, By Disease Indication
    - 7.4.7.2. Market Size and Forecast, By Route Of Administration
    - 7.4.7.3. Market Size and Forecast, By Distribution Channel
  - 7.4.8. India Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.4.8.1. Market Size and Forecast, By Disease Indication
    - 7.4.8.2. Market Size and Forecast, By Route Of Administration
    - 7.4.8.3. Market Size and Forecast, By Distribution Channel
  - 7.4.9. South Korea Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.4.9.1. Market Size and Forecast, By Disease Indication
    - 7.4.9.2. Market Size and Forecast, By Route Of Administration
    - 7.4.9.3. Market Size and Forecast, By Distribution Channel
  - 7.4.10. Australia Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.4.10.1. Market Size and Forecast, By Disease Indication
    - 7.4.10.2. Market Size and Forecast, By Route Of Administration
    - 7.4.10.3. Market Size and Forecast, By Distribution Channel
  - 7.4.11. Thailand Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.4.11.1. Market Size and Forecast, By Disease Indication
    - 7.4.11.2. Market Size and Forecast, By Route Of Administration
    - 7.4.11.3. Market Size and Forecast, By Distribution Channel
  - 7.4.12. Malaysia Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.4.12.1. Market Size and Forecast, By Disease Indication
    - 7.4.12.2. Market Size and Forecast, By Route Of Administration
    - 7.4.12.3. Market Size and Forecast, By Distribution Channel
  - 7.4.13. Indonesia Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.4.13.1. Market Size and Forecast, By Disease Indication
    - 7.4.13.2. Market Size and Forecast, By Route Of Administration
    - 7.4.13.3. Market Size and Forecast, By Distribution Channel
  - 7.4.14. Rest of Asia Pacific Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.4.14.1. Market Size and Forecast, By Disease Indication
    - 7.4.14.2. Market Size and Forecast, By Route Of Administration
    - 7.4.14.3. Market Size and Forecast, By Distribution Channel
- 7.5. LAMEA
  - 7.5.1. Key Market Trends and Opportunities
  - 7.5.2. Market Size and Forecast, By Disease Indication
  - 7.5.3. Market Size and Forecast, By Route Of Administration
  - 7.5.4. Market Size and Forecast, By Distribution Channel
  - 7.5.5. Market Size and Forecast, By Country
  - 7.5.6. Brazil Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.5.6.1. Market Size and Forecast, By Disease Indication
    - 7.5.6.2. Market Size and Forecast, By Route Of Administration
    - 7.5.6.3. Market Size and Forecast, By Distribution Channel
  - 7.5.7. South Africa Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.5.7.1. Market Size and Forecast, By Disease Indication
    - 7.5.7.2. Market Size and Forecast, By Route Of Administration
    - 7.5.7.3. Market Size and Forecast, By Distribution Channel
  - 7.5.8. Saudi Arabia Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.5.8.1. Market Size and Forecast, By Disease Indication
    - 7.5.8.2. Market Size and Forecast, By Route Of Administration
    - 7.5.8.3. Market Size and Forecast, By Distribution Channel
  - 7.5.9. UAE Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.5.9.1. Market Size and Forecast, By Disease Indication
    - 7.5.9.2. Market Size and Forecast, By Route Of Administration
    - 7.5.9.3. Market Size and Forecast, By Distribution Channel
  - 7.5.10. Argentina Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.5.10.1. Market Size and Forecast, By Disease Indication
    - 7.5.10.2. Market Size and Forecast, By Route Of Administration
    - 7.5.10.3. Market Size and Forecast, By Distribution Channel
  - 7.5.11. Rest of LAMEA Non-steroidal Anti-inflammatory Drugs (nsaids) Market
    - 7.5.11.1. Market Size and Forecast, By Disease Indication
    - 7.5.11.2. Market Size and Forecast, By Route Of Administration
    - 7.5.11.3. Market Size and Forecast, By Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top Winning Strategies
- 8.3. Product Mapping Of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top Player Positioning,2022
CHAPTER 9: COMPANY PROFILES
- 9.1. Endo
  - 9.1.1. Company Overview
  - 9.1.2. Key Executives
  - 9.1.3. Company Snapshot
  - 9.1.4. Operating Business Segments
  - 9.1.5. Product Portfolio
  - 9.1.6. Business Performance
  - 9.1.7. Key Strategic Moves and Developments
- 9.2. Merck
  - 9.2.1. Company Overview
  - 9.2.2. Key Executives
  - 9.2.3. Company Snapshot
  - 9.2.4. Operating Business Segments
  - 9.2.5. Product Portfolio
  - 9.2.6. Business Performance
  - 9.2.7. Key Strategic Moves and Developments
- 9.3. Depomed
  - 9.3.1. Company Overview
  - 9.3.2. Key Executives
  - 9.3.3. Company Snapshot
  - 9.3.4. Operating Business Segments
  - 9.3.5. Product Portfolio
  - 9.3.6. Business Performance
  - 9.3.7. Key Strategic Moves and Developments
- 9.4. Yunnan Baiyao
  - 9.4.1. Company Overview
  - 9.4.2. Key Executives
  - 9.4.3. Company Snapshot
  - 9.4.4. Operating Business Segments
  - 9.4.5. Product Portfolio
  - 9.4.6. Business Performance
  - 9.4.7. Key Strategic Moves and Developments
- 9.5. Teva
  - 9.5.1. Company Overview
  - 9.5.2. Key Executives
  - 9.5.3. Company Snapshot
  - 9.5.4. Operating Business Segments
  - 9.5.5. Product Portfolio
  - 9.5.6. Business Performance
  - 9.5.7. Key Strategic Moves and Developments
- 9.6. Johnson And Johnson Services, Inc.
  - 9.6.1. Company Overview
  - 9.6.2. Key Executives
  - 9.6.3. Company Snapshot
  - 9.6.4. Operating Business Segments
  - 9.6.5. Product Portfolio
  - 9.6.6. Business Performance
  - 9.6.7. Key Strategic Moves and Developments
- 9.7. Allergan
  - 9.7.1. Company Overview
  - 9.7.2. Key Executives
  - 9.7.3. Company Snapshot
  - 9.7.4. Operating Business Segments
  - 9.7.5. Product Portfolio
  - 9.7.6. Business Performance
  - 9.7.7. Key Strategic Moves and Developments
- 9.8. Purdue
  - 9.8.1. Company Overview
  - 9.8.2. Key Executives
  - 9.8.3. Company Snapshot
  - 9.8.4. Operating Business Segments
  - 9.8.5. Product Portfolio
  - 9.8.6. Business Performance
  - 9.8.7. Key Strategic Moves and Developments
- 9.9. Pfizer Inc.
  - 9.9.1. Company Overview
  - 9.9.2. Key Executives
  - 9.9.3. Company Snapshot
  - 9.9.4. Operating Business Segments
  - 9.9.5. Product Portfolio
  - 9.9.6. Business Performance
  - 9.9.7. Key Strategic Moves and Developments
- 9.10. GSK Plc
  - 9.10.1. Company Overview
  - 9.10.2. Key Executives
  - 9.10.3. Company Snapshot
  - 9.10.4. Operating Business Segments
  - 9.10.5. Product Portfolio
  - 9.10.6. Business Performance
  - 9.10.7. Key Strategic Moves and Developments
- 9.11. Grunenthal
  - 9.11.1. Company Overview
  - 9.11.2. Key Executives
  - 9.11.3. Company Snapshot
  - 9.11.4. Operating Business Segments
  - 9.11.5. Product Portfolio
  - 9.11.6. Business Performance
  - 9.11.7. Key Strategic Moves and Developments
- 9.12. Bayer AG
  - 9.12.1. Company Overview
  - 9.12.2. Key Executives
  - 9.12.3. Company Snapshot
  - 9.12.4. Operating Business Segments
  - 9.12.5. Product Portfolio
  - 9.12.6. Business Performance
  - 9.12.7. Key Strategic Moves and Developments
- 9.13. Sanofi
  - 9.13.1. Company Overview
  - 9.13.2. Key Executives
  - 9.13.3. Company Snapshot
  - 9.13.4. Operating Business Segments
  - 9.13.5. Product Portfolio
  - 9.13.6. Business Performance
  - 9.13.7. Key Strategic Moves and Developments
- 9.14. Eli Lilly
  - 9.14.1. Company Overview
  - 9.14.2. Key Executives
  - 9.14.3. Company Snapshot
  - 9.14.4. Operating Business Segments
  - 9.14.5. Product Portfolio
  - 9.14.6. Business Performance
  - 9.14.7. Key Strategic Moves and Developments
- 9.15. AstraZeneca
  - 9.15.1. Company Overview
  - 9.15.2. Key Executives
  - 9.15.3. Company Snapshot
  - 9.15.4. Operating Business Segments
  - 9.15.5. Product Portfolio
  - 9.15.6. Business Performance
  - 9.15.7. Key Strategic Moves and Developments

LIST OF TABLES
TABLE 1. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET, BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 2. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET FOR ARTHRITIS, BY REGION, 2022-2032 ($MILLION)
TABLE 3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET FOR MIGRAINE, BY REGION, 2022-2032 ($MILLION)
TABLE 4. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET FOR OPHTHALMIC DISEASES, BY REGION, 2022-2032 ($MILLION)
TABLE 5. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 6. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 7. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
TABLE 8. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET FOR PARENTERAL, BY REGION, 2022-2032 ($MILLION)
TABLE 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET, BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 10. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 12. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 13. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 18. U.S. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 19. U.S. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 20. U.S. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 21. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 22. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 23. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 24. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 25. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 26. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 27. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2022-2032 ($MILLION)
TABLE 28. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 29. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 30. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 31. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 32. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 33. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 34. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 35. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 36. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 37. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 38. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 39. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 40. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 41. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 42. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 43. UK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 44. UK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 45. UK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 46. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 47. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 48. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 49. REST OF EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 50. REST OF EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 51. REST OF EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2022-2032 ($MILLION)
TABLE 53. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 54. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 55. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 56. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 57. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 58. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 59. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 60. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 61. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 62. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 63. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 64. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 65. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 68. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 69. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 70. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 71. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 72. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 73. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 74. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 75. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 76. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 77. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 78. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 79. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 80. REST OF ASIA PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 81. REST OF ASIA PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 82. REST OF ASIA PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 83. LAMEA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2022-2032 ($MILLION)
TABLE 84. LAMEA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 85. LAMEA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 86. LAMEA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 87. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 88. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 89. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 90. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 91. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 92. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 93. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 94. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 95. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 96. UAE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 97. UAE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 98. UAE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 99. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 100. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 101. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 102. REST OF LAMEA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISEASE INDICATION, 2022-2032 ($MILLION)
TABLE 103. REST OF LAMEA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 104. REST OF LAMEA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY DISTRIBUTION CHANNEL , 2022-2032 ($MILLION)
TABLE 105. ENDO: KEY EXECUTIVES
TABLE 106. ENDO: COMPANY SNAPSHOT
TABLE 107. ENDO: OPERATING SEGMENTS
TABLE 108. ENDO: PRODUCT PORTFOLIO
TABLE 109. ENDO: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 110. MERCK: KEY EXECUTIVES
TABLE 111. MERCK: COMPANY SNAPSHOT
TABLE 112. MERCK: OPERATING SEGMENTS
TABLE 113. MERCK: PRODUCT PORTFOLIO
TABLE 114. MERCK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 115. DEPOMED: KEY EXECUTIVES
TABLE 116. DEPOMED: COMPANY SNAPSHOT
TABLE 117. DEPOMED: OPERATING SEGMENTS
TABLE 118. DEPOMED: PRODUCT PORTFOLIO
TABLE 119. DEPOMED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 120. YUNNAN BAIYAO: KEY EXECUTIVES
TABLE 121. YUNNAN BAIYAO: COMPANY SNAPSHOT
TABLE 122. YUNNAN BAIYAO: OPERATING SEGMENTS
TABLE 123. YUNNAN BAIYAO: PRODUCT PORTFOLIO
TABLE 124. YUNNAN BAIYAO: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 125. TEVA: KEY EXECUTIVES
TABLE 126. TEVA: COMPANY SNAPSHOT
TABLE 127. TEVA: OPERATING SEGMENTS
TABLE 128. TEVA: PRODUCT PORTFOLIO
TABLE 129. TEVA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 130. JOHNSON AND JOHNSON SERVICES, INC.: KEY EXECUTIVES
TABLE 131. JOHNSON AND JOHNSON SERVICES, INC.: COMPANY SNAPSHOT
TABLE 132. JOHNSON AND JOHNSON SERVICES, INC.: OPERATING SEGMENTS
TABLE 133. JOHNSON AND JOHNSON SERVICES, INC.: PRODUCT PORTFOLIO
TABLE 134. JOHNSON AND JOHNSON SERVICES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 135. ALLERGAN: KEY EXECUTIVES
TABLE 136. ALLERGAN: COMPANY SNAPSHOT
TABLE 137. ALLERGAN: OPERATING SEGMENTS
TABLE 138. ALLERGAN: PRODUCT PORTFOLIO
TABLE 139. ALLERGAN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 140. PURDUE: KEY EXECUTIVES
TABLE 141. PURDUE: COMPANY SNAPSHOT
TABLE 142. PURDUE: OPERATING SEGMENTS
TABLE 143. PURDUE: PRODUCT PORTFOLIO
TABLE 144. PURDUE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 145. PFIZER INC.: KEY EXECUTIVES
TABLE 146. PFIZER INC.: COMPANY SNAPSHOT
TABLE 147. PFIZER INC.: OPERATING SEGMENTS
TABLE 148. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 149. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 150. GSK PLC: KEY EXECUTIVES
TABLE 151. GSK PLC: COMPANY SNAPSHOT
TABLE 152. GSK PLC: OPERATING SEGMENTS
TABLE 153. GSK PLC: PRODUCT PORTFOLIO
TABLE 154. GSK PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 155. GRUNENTHAL: KEY EXECUTIVES
TABLE 156. GRUNENTHAL: COMPANY SNAPSHOT
TABLE 157. GRUNENTHAL: OPERATING SEGMENTS
TABLE 158. GRUNENTHAL: PRODUCT PORTFOLIO
TABLE 159. GRUNENTHAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 160. BAYER AG: KEY EXECUTIVES
TABLE 161. BAYER AG: COMPANY SNAPSHOT
TABLE 162. BAYER AG: OPERATING SEGMENTS
TABLE 163. BAYER AG: PRODUCT PORTFOLIO
TABLE 164. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 165. SANOFI: KEY EXECUTIVES
TABLE 166. SANOFI: COMPANY SNAPSHOT
TABLE 167. SANOFI: OPERATING SEGMENTS
TABLE 168. SANOFI: PRODUCT PORTFOLIO
TABLE 169. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 170. ELI LILLY: KEY EXECUTIVES
TABLE 171. ELI LILLY: COMPANY SNAPSHOT
TABLE 172. ELI LILLY: OPERATING SEGMENTS
TABLE 173. ELI LILLY: PRODUCT PORTFOLIO
TABLE 174. ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 175. ASTRAZENECA: KEY EXECUTIVES
TABLE 176. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 177. ASTRAZENECA: OPERATING SEGMENTS
TABLE 178. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 179. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES
FIGURE 1. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SEGMENTATION
FIGURE 2. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET
FIGURE 3. SEGMENTATION NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET
FIGURE 4. TOP INVESTMENT POCKET IN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET
FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
FIGURE 8. LOW THREAT OF SUBSTITUTION
FIGURE 9. HIGH COMPETITIVE RIVALRY
FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALNON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET
FIGURE 11. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SEGMENTATION, BY BY DISEASE INDICATION
FIGURE 12. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET FOR ARTHRITIS, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 13. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET FOR MIGRAINE, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 14. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET FOR OPHTHALMIC DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 15. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 16. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SEGMENTATION, BY BY ROUTE OF ADMINISTRATION
FIGURE 17. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET FOR ORAL, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 18. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET FOR PARENTERAL, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 19. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
FIGURE 20. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 21. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 22. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 23. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
FIGURE 24. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
FIGURE 25. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
FIGURE 26. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 27. COMPETITIVE DASHBOARD
FIGURE 28. COMPETITIVE HEATMAP: NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET
FIGURE 29. Top player positioning, 2022
FIGURE 30. ENDO: NET SALES, 2020-2022 ($MILLION)
FIGURE 31. ENDO: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 32. ENDO: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 33. MERCK: NET SALES, 2020-2022 ($MILLION)
FIGURE 34. MERCK: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 35. MERCK: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 36. DEPOMED: NET SALES, 2020-2022 ($MILLION)
FIGURE 37. DEPOMED: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 38. DEPOMED: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 39. YUNNAN BAIYAO: NET SALES, 2020-2022 ($MILLION)
FIGURE 40. YUNNAN BAIYAO: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 41. YUNNAN BAIYAO: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 42. TEVA: NET SALES, 2020-2022 ($MILLION)
FIGURE 43. TEVA: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 44. TEVA: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 45. JOHNSON AND JOHNSON SERVICES, INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 46. JOHNSON AND JOHNSON SERVICES, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 47. JOHNSON AND JOHNSON SERVICES, INC.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 48. ALLERGAN: NET SALES, 2020-2022 ($MILLION)
FIGURE 49. ALLERGAN: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 50. ALLERGAN: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 51. PURDUE: NET SALES, 2020-2022 ($MILLION)
FIGURE 52. PURDUE: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 53. PURDUE: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 54. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 55. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 56. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 57. GSK PLC: NET SALES, 2020-2022 ($MILLION)
FIGURE 58. GSK PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 59. GSK PLC: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 60. GRUNENTHAL: NET SALES, 2020-2022 ($MILLION)
FIGURE 61. GRUNENTHAL: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 62. GRUNENTHAL: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 63. BAYER AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 64. BAYER AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 65. BAYER AG: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 66. SANOFI: NET SALES, 2020-2022 ($MILLION)
FIGURE 67. SANOFI: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 68. SANOFI: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 69. ELI LILLY: NET SALES, 2020-2022 ($MILLION)
FIGURE 70. ELI LILLY: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 71. ELI LILLY: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 72. ASTRAZENECA: NET SALES, 2020-2022 ($MILLION)
FIGURE 73. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 74. ASTRAZENECA: REVENUE SHARE, BY REGION, 2032 (%)

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

U.S.-Canada Toll-free: +1-800-792-5285
Int'l :	+1-503-894-6022
Europe :	+44-845-528-1300
Email :	help@alliedmarketresearch.com

Life Sciences	Construction & Manufacturing	Semiconductor & Electronics
Consumer Goods	Food & Beverages	Automotive & Tarnsportation
Materials & Chemicals	Energy & Power	ICT & Media
Aerospace & Defense	BFSI
You must check at least one industry.

Your Shopping Cart Is Empty

Continue Shopping

Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Global Opportunity Analysis and Industry Forecast, 2023-2032

2023

Non-steroidal Anti-inflammatory Drugs (nsaids) Market

Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market

by Disease Indication (Arthritis, Migraine, Ophthalmic Diseases, Others), by Route of Administration (Oral, Parenteral) and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032

COVID-19

CHAPTER 1: INTRODUCTION

1.1. Report Description

1.2. Key Market Segments

1.3. Key Benefits

1.4. Research Methodology

1.4.1. Primary Research

1.4.2. Secondary Research

1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope

3.2. Key Findings

3.2.1. Top Investment Pockets

3.2.2. Top Winning Strategies

3.3. Porter's Five Forces Analysis

3.3.1. Bargaining Power of Suppliers

3.3.2. Threat of New Entrants

3.3.3. Threat of Substitutes

3.3.4. Competitive Rivalry

3.3.5. Bargaining Power among Buyers

3.5. Market Dynamics

3.5.1. Drivers

3.5.2. Restraints

3.5.3. Opportunities

3.6. COVID-19 Impact Analysis

CHAPTER 4: NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET, BY DISEASE INDICATION

4.1. Market Overview

4.1.1 Market Size and Forecast, By Disease Indication

4.2. Arthritis

4.2.1. Key Market Trends, Growth Factors and Opportunities

4.2.2. Market Size and Forecast, By Region

4.2.3. Market Share Analysis, By Country

4.3. Migraine

4.3.1. Key Market Trends, Growth Factors and Opportunities

4.3.2. Market Size and Forecast, By Region

4.3.3. Market Share Analysis, By Country

4.4. Ophthalmic Diseases

4.4.1. Key Market Trends, Growth Factors and Opportunities

4.4.2. Market Size and Forecast, By Region

4.4.3. Market Share Analysis, By Country

4.5. Others

4.5.1. Key Market Trends, Growth Factors and Opportunities

4.5.2. Market Size and Forecast, By Region

4.5.3. Market Share Analysis, By Country

CHAPTER 5: NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET, BY ROUTE OF ADMINISTRATION

5.1. Market Overview

5.1.1 Market Size and Forecast, By Route Of Administration

5.2. Oral

5.2.1. Key Market Trends, Growth Factors and Opportunities

5.2.2. Market Size and Forecast, By Region

5.2.3. Market Share Analysis, By Country

5.3. Parenteral

5.3.1. Key Market Trends, Growth Factors and Opportunities

5.3.2. Market Size and Forecast, By Region

5.3.3. Market Share Analysis, By Country

CHAPTER 6: NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET, BY DISTRIBUTION CHANNEL

6.1. Market Overview

6.1.1 Market Size and Forecast, By Distribution Channel

6.2. Hospital Pharmacy

6.2.1. Key Market Trends, Growth Factors and Opportunities

6.2.2. Market Size and Forecast, By Region

6.2.3. Market Share Analysis, By Country

6.3. Retail Pharmacy

6.3.1. Key Market Trends, Growth Factors and Opportunities

6.3.2. Market Size and Forecast, By Region

6.3.3. Market Share Analysis, By Country

6.4. Online Pharmacy

6.4.1. Key Market Trends, Growth Factors and Opportunities

6.4.2. Market Size and Forecast, By Region

6.4.3. Market Share Analysis, By Country

CHAPTER 7: NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET, BY REGION

Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market
Global Opportunity Analysis and Industry Forecast, 2023-2032